News

Back to the list

Round Table "Localisation of Pharmaceutical Production in Russia: Yesterday, Today and Tomorrow"

10.04.2015

L—R: Frank Schauff, AEB CEO; Vladimir Emelianov, Deputy Head of the Department of State Regulation of the Medicines Turnover, Ministry of Health of the Russian Federation; Dmitry Kolobov, Deputy Head of the Department for Development of Pharmaceutical and Medical Industry, Ministry of Industry and Trade of the Russian Federation. 

On 10 April 2015, the AEB took part in the Round Table "Localisation of Pharmaceutical Production in Russia: Yesterday, Today and Tomorrow" which took place in Kaluga’s pharmaceutical cluster. The AEB was represented by Frank Schauff, AEB CEO, and Sergey Smirnov, Chairman of the AEB Health & Pharmaceuticals Committee, Vice President, Novo Nordisk. The Round Table was dedicated to issues such as localisation in the new economic conditions; definition of the local product: its current status and prospects; long-term contracts with pharmaceutical manufacturers; parallel imports in the Russian Federation, and the fight against counterfeiting, the harmonisation of standards in the Eurasian Economic Union. The event was co-organised by the Association of Russian Pharmaceutical Manufacturers, the Kaluga Region Government and the Round Table of the EU-Russia Industrialists. Among the attendees  were representatives of relevant ministries: the Ministry of Health of the Russian Federation, the Ministry of Industry and Trade, regional ministries, representatives of NP "Kaluga pharmaceutical cluster" as well as representatives of pharmaceutical companies. The conclusions of the Round Table will be submitted to the attention of the State Council of the Russian Federation. The Round Table followed the Ceremony of the Inauguration of Novo Nordisk’s Manufacturing Facility in Kaluga.

Кр-стол3_Калуга_10.04.2015_.jpg

L—R: participant of the Round Table; Inna Panteleeva, Legal and Compliance Director, Novo Nordisk; Sergey Smirnov, Chairman of the AEB Health & Pharmaceuticals Committee, Vice President, Novo Nordisk.



Share: